Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Malaria Chemotherapy: Recent Advances in Drug Development.

17:01 EDT 20th April 2014 | BioPortfolio

Summary of "Malaria Chemotherapy: Recent Advances in Drug Development."

Malaria is a disease caused by parasitic protozoa of the genus Plasmodium. Despite significant advances in understanding the disease and the parasite biology, malaria still remains one of the leading causes of morbidity and mortality, particularly in malaria-endemic regions of the world. The main factor hampering malaria control is the high degree of resistance developed by Plasmodium species against several classes of drugs. Artemisinin-based Combination Therapy (ACT) is the most rapidly acting antimalarial treatment effective against multi-drug resistant strains, and is, at present, the only group of antimalarial drugs to which resistance by Plasmodium falciparum has not developed yet in the field, even though the isolation of artemisinin-resistant strains is raising concern. As a result, discovering and developing novel antimalarial agents is one of the greatest challenges facing malaria control today. This review covers patent literature from 2007 to date regarding small molecules or natural compounds targeting the asexual forms of the parasite. Recent patents filed and issued for ameliorating conventional antimalarial treatment methods by non-conventional dosage forms are also reviewed.

Affiliation

Department of Pharmaceutical and Applied Chemistry, University of Siena, via Aldo Moro 2, 53100 Siena, Italy. @unisi.it.

Journal Details

This article was published in the following journal.

Name: Recent patents on anti-infective drug discovery
ISSN: 1574-891X
Pages:

Links

PubMed Articles [19150 Associated PubMed Articles listed on BioPortfolio]

The Combination of Chemotherapy and Radiotherapy towards More Efficient Drug Delivery.

Research on anticancer therapies has advanced significantly in recent years. New therapeutic platforms that can further improve the health of patients are still highly demanded. We propose the idea of...

Recent highlights in anti-protozoan drug development and resistance research.

This article summarizes the highlights of research presented in January, 2012, at the Keystone Symposium on "Drug Discovery for Protozoan Parasites" held in Santa Fe, New Mexico. This symposium which...

Recent Advances in Detection of Plasmodium ovale: Implications of Separation into the Two Species Plasmodium ovale wallikeri and Plasmodium ovale curtisi.

Recent molecular studies indicate that Plasmodium ovale malaria is caused by two closely related species of protozoan parasites, thereby imposing new challenges for detection and species differentiati...

Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements.

Vector-borne protozoan diseases represent a serious public health challenge, especially in the tropics where poverty together with vector-favorable climates are the aggravating factors. Each of the va...

Advances in nanomedicine for head and neck cancer.

The quality of life of patients with head and neck squamous cell carcinoma (HNSCC) has been improved because of advances in surgical and radiotherapeutic techniques as well as organ-preservation metho...

Clinical Trials [2929 Associated Clinical Trials listed on BioPortfolio]

Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)

Artemisinin combination therapy (ACT) with artemether lumefantrine (AL) is currently the first line treatment policy in Tanzania. AL is an efficacious drug that also has the capacity to re...

A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children

A recent study has shown that the administration of a single dose of sulfadoxine/pyrimethamine plus artesunate to Senegalese children on three occasions during a short malaria transmission...

Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal

The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria...

Malaria Prevalence in Children

The purpose of this pilot study is to evaluate the use of (1) 'malaria prevalence', (2) 'malaria incidence' and (3) 'malaria mortality' as a measure of malaria transmission in The Gambia,...

Sporozoite Challenge of Polyprotein Vaccinees

This study examines the ability of two new malaria vaccines (FP9-PP and MVA-PP) to prevent the development of malaria infection after controlled exposure to the parasite. Volunteers for th...

Medical and Biotech [MESH] Definitions

A biguanide compound which has little antimalarial activity until metabolized in the body to the active antimalarial agent cycloguanil. The usefulness of proguanil is limited by the rapid development of drug resistance by the malarial parasite. The hydrochloride is used for the casual prophylaxis of falciparum malaria, to suppress other forms of malaria, and to reduce transmission of infection (From Martindale, The Extra Pharmacopoeia, 30th ed, p405)

Educational programs designed to inform nurses of recent advances in their fields.

Educational programs designed to inform physicians of recent advances in their field.

Educational programs designed to inform dentists of recent advances in their fields.

Educational programs designed to inform graduate pharmacists of recent advances in their particular field.

Search BioPortfolio: